Harvard Bioscience price to free cash flow HBIO

Market value divided by free cash flow over the last twelve months, since 2019.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 15.3×; Aug 2026
8-year median: 19.9×
8-year range: 3.0× to 120×
Peer median: 11.8×

Harvard Bioscience's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Aug 2026, at 15.3×.

On the days it had one over the last 8 years, its median was 19.9×, from 3.0× in Feb 2026 to 120× in Nov 2021.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	15.3×	3.0×	15.3×
2025	4.2×	3.3×	110×
2024	102×	10.4×	117×
2023	20.4×	15.2×	72.1×
2022	92.7×	78.1×	99.4×
2021	105×	21.8×	120×
2020	22.2×	8.4×	23.3×
2019	14.8×	14.2×	91.1×

Against its peers

Companies in Healthcare nearest Harvard Bioscience's size, closest first, today.

Company	Price to free cash flow
HBIOHarvard Bioscience	n/m
NEPHNephros	n/m
ATNMActinium Pharmaceuticals	n/m
APTAlpha Pro Tech	9.7×
SPROSpero Therapeutics	n/m
LFVNLifevantage	11.0×
ICCCImmucell	22.1×
KEQUKewaunee Scientific	8.7×
PDEXPro DEX	29.5×
PLXProtalix BioTherapeutics	26.8×
NATRNatures Sunshine Products	11.8×
Peer median	11.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Harvard Bioscience

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.